• 1. Exchangeability of amino acid residues with similar physicochemical properties in coiled-coil interactions?
  Guiying Zhang,Maosheng Cheng,Yanni Li,Keliang Liu,Lifeng Cai Chem. Commun., 2013,49, 11086-11088
• 2. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502
• 3. Excitation dependent recombination studies on SnO2/TiO2 electrospun nanofibers?
  Veluru Jagadeesh babu,Sesha Vempati RSC Adv., 2015,5, 66367-66375
• 4. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 5. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ketones
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Carbonyl compounds Ketones

Professional Introduction to Compound with CAS No. 1125-28-6 and Product Name: 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone

The compound with the CAS number 1125-28-6 and the product name 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone represents a significant area of interest in the field of pharmaceutical chemistry and medicinal biology. This compound, characterized by its pyrazole core structure, has garnered attention due to its versatile pharmacological properties and potential applications in drug discovery. The 1,3,5-trimethyl substitution pattern on the pyrazole ring contributes to its unique chemical and biological behavior, making it a valuable scaffold for developing novel therapeutic agents.

In recent years, the exploration of heterocyclic compounds has been a cornerstone in the development of new drugs. Pyrazole derivatives, in particular, have shown promise in various therapeutic areas, including anti-inflammatory, antimicrobial, and anticancer applications. The structural motif of 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone allows for easy functionalization at multiple sites, enabling chemists to tailor its properties for specific biological targets. This flexibility has made it a favorite among researchers seeking to develop small-molecule inhibitors and activators.

One of the most compelling aspects of this compound is its interaction with biological targets. The pyrazole ring is known to exhibit strong binding affinity with enzymes and receptors due to its ability to form hydrogen bonds and hydrophobic interactions. In particular, studies have shown that derivatives of pyrazole can modulate the activity of enzymes involved in metabolic pathways relevant to diseases such as diabetes and cancer. The presence of the 1,3,5-trimethyl group enhances the lipophilicity of the molecule, improving its ability to cross cell membranes and reach intracellular targets.

Recent advancements in computational chemistry have further accelerated the discovery process for compounds like 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone. Molecular docking simulations have been instrumental in predicting how this compound might interact with various protein targets. For instance, researchers have utilized these techniques to explore its potential as an inhibitor of kinases and other enzymes implicated in tumor growth. The results from these simulations have guided experimental efforts toward optimizing the compound's pharmacokinetic properties.

The synthesis of 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone involves multi-step organic reactions that highlight the ingenuity of modern synthetic methodologies. Key steps include condensation reactions between appropriately substituted pyrazole derivatives and acetylating agents. The choice of reagents and reaction conditions is critical to achieving high yields and purity. Advances in green chemistry have also influenced these synthetic routes, with an emphasis on minimizing waste and using sustainable solvents.

In clinical research settings, derivatives of pyrazole have been investigated for their potential therapeutic effects. For example, some studies have demonstrated that certain pyrazole-based compounds can exhibit anti-inflammatory properties by inhibiting cyclooxygenase (COX) enzymes or modulating cytokine production. While more research is needed to fully understand the mechanisms of action for 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone, these findings suggest that it could be a promising candidate for treating inflammatory disorders.

The role of structural biology in drug discovery cannot be overstated. High-resolution crystal structures of protein targets complexed with pyrazole derivatives have provided invaluable insights into their binding modes. These structures help medicinal chemists design analogs with improved potency and selectivity. In particular, understanding how the pyrazole ring interacts with specific residues in the target protein can guide modifications that enhance binding affinity while minimizing off-target effects.

As interest in personalized medicine grows, so does the demand for compounds that can be easily modified to suit individual patient needs. The modular nature of 1-(1,3,5-Trimethyl-1H-pyrazol-4-yl)ethanone makes it an ideal candidate for such applications. By introducing different substituents at strategic positions on the molecule, researchers can create libraries of compounds tailored to specific biological pathways or genetic profiles.

The future prospects for this compound are bright given its diverse range of potential applications. Ongoing research aims to expand its utility into new therapeutic areas such as neurodegenerative diseases and infectious disorders. Collaborative efforts between academia and industry are essential to translate laboratory findings into clinical reality.

• 31539-68-1(Phenyl(1,3,5-trimethyl-1H-pyrazol-4-yl)methanone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)